Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Aug;69(4):305–317. doi: 10.1016/j.curtheres.2008.08.004

Comparison of methimazole/hydrocortisone ointment with oral methimazole in patients with graves disease: A prospective, randomized, open-label, parallel-group, 18-month study

Ling Chen 1,*, Hong-qing Wang 2, Yan-yan Gao 3, Jun Liang 4, Men Wang 5, Jie Bai 6, Wen-bo Qi 7, Jun-sheng Zhang 1, Jian Zhang 8, Juan-qing Ren 8, Hui-qing Li 9
PMCID: PMC3969956  PMID: 24692808

Abstract

Background: Thionamide antithyroid drugs (ATDs) have certain disadvantages and are associated with some adverse events (AEs). To overcome the problems associated with ATDs, a compound antithyroid ointment (CATO) containing methimazole (MMI) and hydrocortisone has been developed for use as a local thyroid treatment (LTT).

Objective: The aim of this study was to assess the clinical effectiveness and tolerability of CATO LTT in patients with Graves disease (GD).

Methods: This was a prospective, randomized, open-label, parallel-group clinical trial conducted at the Provincial Hospital Affiliated to Shandong University (Jinan, China). Patients with GD aged 19 to 65 years were randomized to receive either CATO LTT 0.3 g/d or oral MMI 37.5 mg/d (control group) treatment for 18 months, with a 4-year follow-up period. Hyperthyroid symptoms, thyroid function, granulocyte count, liver function, and AEs were assessed at baseline and every 2 weeks until serum thyroid hormone (TH) concentration normalized, at which point patients were assessed monthly. The primary efficacy end points were the duration of treatment required for serum TH concentration to normalize and the remission rate after completing the 18-month treatment regimen.

Results: A total of 154 patients (133 women, 21 men; mean [SD] age, 39.6 [11.8] years; all Han Chinese) participated in the study; all patients completed the 18-month treatment period. Compared with the MMI group (n 76), the CATO- treated group (n 78) had a significantly shorter median (range) time to restoration of normal serum thyroid hormone concentration (43 [12–150] vs 22 [7–60] days; P < 0.001), a significantly lower rate of recurrence of hyperthyroidism (309/1520 [20.3%] vs 193/1368 [14.1%] person-time; P < 0.001), a significantly lower drug hypothyroidism rate (185/1520 [12.2%] vs 54/1368 [3.9%] person-time; P < 0.001), and a higher remission rate (year 1:46/69 [66.7%] vs 65/72 [90.3%] patients, P 0.001; year 2:40/69 [58.0%] vs 60/72 [83.3%] patients, P - 0.001; year 3:34/69 [49.3%] vs 57/72 [79.2%] patients, P < 0.001; and year 4:30/69 [43.5%] vs 55/72 [76.4%] patients, P < 0.001). Systemic AEs occurred in 6 patients (7.9%) in the MMI group (drug neutropenia, 2 patients [2.6%]; epistaxis, 1 [1.3%]; hepatopathy, 1 [1.3%]; and other systemic AEs, 2 [2.6%]), while no systemic AEs were observed/reported in the CATO group.

Conclusion: This study suggests that CATO LTT was well tolerated and more effective than oral MMI treatment in controlling thyrotoxicosis and promoting remission of GD in these Han Chinese patients.

Key Words: hyperthyroidism, treatment, antithyroid drugs, transdermal administration, ointment

Full Text

The Full Text of this article is available as a PDF (727.9 KB).

Footnotes

This study was presented in part at the 28th Annual Meeting of the American College of Clinical Pharmacology, September 16–18, 1999, Rockville, Maryland.

References

  • 1.Feldt-Rasmussen U, Glinoer D, Orgiazzi J. Reassessment of antithyroid drug therapy of Graves' disease. Annu Rev Med. 1993;44:323–334. doi: 10.1146/annurev.me.44.020193.001543. [DOI] [PubMed] [Google Scholar]
  • 2.Mori T, Sugawa H, Kosugi S. Recent trends in the management of Graves' hyperthyroidism in Japan: Opinion survey results, especially on the combination therapy of antithyroid drug and thyroid hormone. Endocr J. 1997;44:509–517. doi: 10.1507/endocrj.44.509. [DOI] [PubMed] [Google Scholar]
  • 3.Durman KD. The thyroid gland: Hyperthyroidism. In: Becker KL, Bilezikian JP, Loriaux DL, editors. Principles and Practice of Endocrinology and Metabolism. Pa: Lippincott; Philadelphia: 1990. pp. 331–347. [Google Scholar]
  • 4.Parfitt K. Martindale: The Complete Drug Reference. 32nd ed. Pharmaceutical Press; London, UK: 1999. Thyroid and antithyroid drugs: Methimazole; pp. 1489–1500. [Google Scholar]
  • 5.Allannic H, Lorcy Y, Leguerrier AM. Synthetic antithyroid drugs and Basedow's disease or the choice of a therapeutic strategy. Presse Med. 1991;20:645–651. [PubMed] [Google Scholar]
  • 6.Cooper DS. The side effects of antithyroid drugs. Endocrinology. 1999;9:457–467. [Google Scholar]
  • 7.Cooper DS. Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease. Endocrinol Metab Clin North Am. 1998;27:225–247. doi: 10.1016/s0889-8529(05)70308-x. [DOI] [PubMed] [Google Scholar]
  • 8.Page SR, Sheard CE, Herbert M. A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin Endocrinol. 1996;45:511–516. doi: 10.1046/j.1365-2265.1996.00800.x. [published correction appears in Clin Endocrinol 1997;46:240] [DOI] [PubMed] [Google Scholar]
  • 9.Gao Y, Kong WL, Gao YM. Correlation between serum antithyroid antibody titer and changes in thyroid function during therapy of Graves' disease with antithyroid drugs. Zhonghua Nei Ke Za Zhi. 1987;26:86–89. [in Chinese] 125. [PubMed] [Google Scholar]
  • 10.Kallner G, Vitals S, Ljunggren JG. Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease. Intern Med. 1996;239:525–529. doi: 10.1046/j.1365-2796.1996.489827000.x. [DOI] [PubMed] [Google Scholar]
  • 11.Axelrod L. Corticosteroid therapy. In: Becker KL, Bilezikian JP, Loxiaux DL, editors. Principles and Practice of endocrinology and Metabolism. Lippincott; Philadelphia, Pa: 1990. pp. 613–623. [Google Scholar]
  • 12.Sun HY, Zhu C, Cui XP. Comparison of the therapeutic effects on patients with Graves' disease between different modes of medication by HPLC. Acta Acad Ned Shandong. 2000;38:218–220. [Google Scholar]
  • 13.Chen L, Zhang J, Ren JQ. The treatment of antithyroid cream made by ourselves for Graves' disease. Shandong Med J. 1994;34:16–17. [Google Scholar]
  • 14.Chen L, Zhang J-S. A preliminary clinical trial of topical treatment with compound methimazole ointment to thyrotoxicosis. Shandong Med J. 2008;48:45–46. [Google Scholar]
  • 15.Cooper DS. Antithyroid drugs in the management of patients with Graves' disease: An evidence- based approach to therapeutic controversies. J Clin Endocrinol Metab. 2003;88:3474–3481. doi: 10.1210/jc.2003-030185. [DOI] [PubMed] [Google Scholar]
  • 16.Maugendre D, Gatel A, Campion L. Antithyroid drugs and Graves' disease—prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf). 1999;50:127–132. doi: 10.1046/j.1365-2265.1999.00629.x. [DOI] [PubMed] [Google Scholar]
  • 17.Yu SL. 2nd ed. Vol. 422. Peoples' Health Publishing House; Beijing, China: 2005. (Medical Statistics). [Google Scholar]
  • 18.Zimmermann M, Saad A, Hess S. Thyroid ultrasound compared with World Health Organization 1960 and 1994 palpation criteria for determination of goiter prevalence in regions of mild and severe iodine deficiency. Eur J Endocrinol. 2000;143:727–731. doi: 10.1530/eje.0.1430727. [DOI] [PubMed] [Google Scholar]
  • 19.Liao RY. Hyperthyroidism. In: Wang JY, editor. Internal Medicine. Peoples' Health Publishing House; Beijing, China: 2002. pp. 876–889. [Google Scholar]
  • 20.Zhao WJ, Xu JF, Liu M. The promotive action of laurocapram on transdermal absorption of methimazde. Chin Hosp Pharm J. 1997;17:502–503. [Google Scholar]
  • 21.Zhang FC, Qian HH, Gan DQ. The study of transdermal absorption on methimazole. Chin Pharm J. 1989;24:601–659. [Google Scholar]
  • 22.Liu XQ, Geng F, Wang SL. Pharmacokinetics of thiamazole following transdermal administration in rats. J Chin Pharm Univer. 2005;36:342–345. [Google Scholar]
  • 23.Zhao WJ, Yang YG, Zhang M. Study of pharmacokinetics for percutaneous absorption of thiamazole ointment in rabbits. Chin Hosp Pharm J. 1999;19:714–716. [Google Scholar]
  • 24.Buijtels JJ, Kurvers IA, Galac S. Transdermal carbimazole for the treatment of feline hyperthyroidism. Tijdschr Diergeneeskd. 2006;131:478–482. [in Dutch] [PubMed] [Google Scholar]
  • 25.Léuyer M, Prini S, Dunn ME, Doucet MY. Clinical efficacy and safety of transdermal methimazole in the treatment of feline hyperthyroidism. Can Vet J. 2006;47:131–135. doi: 10.4141/cjas67-019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Sarror LL, Trepanier LA, Kroll MM. Efficacy and safety of transdermal merhimazde in the treatment of cats with hyperthyroidism. J Vet Intern Med. 2004;18:651–655. doi: 10.1892/0891-6640(2004)18<651:easotm>2.0.co;2. [DOI] [PubMed] [Google Scholar]
  • 27.Hoffmann G, Marks SL, Taboada J. Transdermal methimazole treatment in cats with hyperthyroidism. J Feline Med Surg. 2003;5:77–82. doi: 10.1016/S1098-612X(02)00095-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Lid Y. Rapid preoperative preparation for severe hyperthyroid Graves' disease. J Clin Endocrinol Metab. 2004;89:5866–5867. doi: 10.1210/jc.2004-1276. author reply 5867. [DOI] [PubMed] [Google Scholar]
  • 29.Wimpfheimer C, Stäubli M, Schäidelin J, Studer H. Prednisone in amiodaronc-induced thyro-toxicosis. Br Med J. 1982;284:1835–1836. doi: 10.1136/bmj.284.6332.1835-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Panzer C, Beazley R, Braverman L. Rapid preoperative preparation for severe hyperthyroid Graves' disease. J Clin Endocrinol Metab. 2004;89:2142–2144. doi: 10.1210/jc.2003-031981. [DOI] [PubMed] [Google Scholar]
  • 31.Larsen PR. Endocrine and reproductive disease: The thyroid. In: Wyngaarden JB, Smith LH, editors. Cecil Textbook of Medicine. 17th. Saunders; Philadelphia, Pa: 1985. pp. 1275–1300. [Google Scholar]
  • 32.Levey GS, Klein I. Disorders of the endocrine gland: Disorders of the thyroid. In: Stein JH, editor. Internal Medicine. 15th. Mosby Inc; St. Louis, Mo: 1998. pp. 1797–1817. [Google Scholar]
  • 33.George J, Joshi SR. Drugs and thyroid. J Assoc Physicians India. 2007;55:215–223. [PubMed] [Google Scholar]
  • 34.Broussolle C, Ducottet X, Martin C. Rapid effectiveness of prednisone and thionamides combined therapy in severe amiodarone iodine-induced thyrotoxicosis. Comparison of two groups of patients with apparently normal thyroid glands. J Enodocrinol Invest. 1989;12:37–42. doi: 10.1007/BF03349916. [DOI] [PubMed] [Google Scholar]
  • 35.Bartalena L, Brogioni S, Grasso L. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: Results of a prospective study. J Clin Endocrinol Metab. 1996;81:2930–2933. doi: 10.1210/jcem.81.8.8768854. [DOI] [PubMed] [Google Scholar]
  • 36.Bogazzi F, Bartalena L, Tomisti L. Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. J Clin Endocrinal Metab. 2007;92:556–562. doi: 10.1210/jc.2006-2059. [published correction appears in J Clin Endocrinol Metab, 2007;92:1325] [DOI] [PubMed] [Google Scholar]
  • 37.Henley DE, Kaye JM, Nguyen HH, Walsh JP. Rapid preparation of patients with Graves' hyperthyroidism for urgent thyroidectomy. Intern Med J. 2006;36:63–64. doi: 10.1111/j.1445-5994.2005.00988.x. [DOI] [PubMed] [Google Scholar]
  • 38.Ozawa Y, Daida H, Shimizu T, Shishiba Y. Rapid improvement of thyroid function by using glucocorticdd indicated for the preoperative preparation of subtotal thyroidectomy in Graves' disease. Endocrinol Jpn. 1983;30:93–100. doi: 10.1507/endocrj1954.30.93. [DOI] [PubMed] [Google Scholar]
  • 39.Jude EB, Dale J, Kumar S, Dodson PM. Treatment of thyrotoxicosis resistant to carbimazole with corticosteroids. Postgrad Med J. 1996;72:489–491. doi: 10.1136/pgmj.72.850.489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Mori T, Sugawa H, Kosugi S. Effectiveness of a short-term steroid treatment on the reduction in goiter size in antithyroid drug-treated patients with Graves' disease. Endocr J. 1997;44:575–580. doi: 10.1507/endocrj.44.575. [DOI] [PubMed] [Google Scholar]
  • 41.Wu KM. The effective observation of 80 patients with hyperthyroidism by local injection of acetic hydroprednisone. Fujian Med J. 1997;19:9–10. [Google Scholar]
  • 42.Liu ZM, Gu MJ, Zou JJ. The study of efficacy and safety of hyperthyroidism with local injection of immunosuppressants and other medicines. Shanghai Med J. 2003;26:1820. [Google Scholar]
  • 43.Nagata I, Aoki N, Wakisaka G. Treatment of thyroid diseases with intrathyroidal injection of glucocorticoid. Nippon Naibunpi Gakkai Zasshi. 1974;50:774–787. doi: 10.1507/endocrine1927.50.4_774. [in Japanese] [DOI] [PubMed] [Google Scholar]
  • 44.Gamstedt A, Kåigedal B, Tegler L. Serum free thyroid hormones are decreased by betamethasone treatment in Graves' disease. Horm Metab Res. 1988;20:54–56. doi: 10.1055/s-2007-1010747. [DOI] [PubMed] [Google Scholar]
  • 45.Clark JH, Schrader WT, O'Malley BW. Mechanism of steroid action. In: Wilson JD, Foster DW, editors. William's Textbook of Endocrinology. Saunders; Philadelphia, Pa: 1985. pp. 33–75. [Google Scholar]
  • 46.Cidlowski JA, King KL, Evans-Storms RB. The biochemistry and molecular biology of glucocorticdd-induced apoptosis in the immune system. Recent Prog Norm Res. 1996;51:457–490. [PubMed] [Google Scholar]
  • 47.Wu XH, Liu C, Liu CP. Effect of glucocorticoid on apoptosis in cultured thyrocytes from patients with Graves' disease. Jiangsu Med J. 2001;27:172–174. [Google Scholar]
  • 48.Yamazaki K, Kanaji Y, Shizume K. Effects of inorganic iodide and adrenocortical steroid on the expression of vascular endothelial growth factor (VEGF) mRNA in Graves' thyroid cell; Presented at: 69th Annual Meeting of the Japan Endocrine Society; Japan: Osaka; July 1996. [Google Scholar]
  • 49.Aguayo J, Iitaka M, Row VV, Volpé R. Studies of HLA-DR expression on cultured human thyrocytes: Effect of antithyroid drugs and other agents on interferon-gamma-induced HLA-DR expression. J Clin Endocrinol Metab. 1988;66:903–908. doi: 10.1210/jcem-66-5-903. [DOI] [PubMed] [Google Scholar]
  • 50.Wenzel KW, Lente JR. Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves' disease: Evidence against an immunosuppressive action of thionamide drugs. J Clin Endocrinol Metab. 1984;58:62–69. doi: 10.1210/jcem-58-1-62. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES